Skip to main content
SpringerLink
Log in

The effects of beraprost sodium on renal function and cardiometabolic profile in patients with diabetes mellitus: a systematic review and meta-analysis of clinical trials

  • Nephrology - Review
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

This systematic review and meta-analysis aimed to assess renal function and cardiometabolic biomarkers after treatment with beraprost sodium in patients with diabetes mellitus.

Methods

We systemically searched PubMed, Embase, Scopus, Web of Science, and Cochrane Library up to August 2020. Statistical heterogeneities were computed using Cochrane’s Q test and I2 test. A fixed- or random-effects model was used to calculate the weighted mean difference (WMD) and corresponding 95% confidence intervals (CI).

Results

From 341citations, seven trials were included into our meta-analysis. Our findings demonstrated that beraprost sodium intake significantly decreased blood urea nitrogen (BUN) (WMD = −5.62, 95% CI [−8.49, −2.74], P < 0.001) and cystatin C (WMD = −0.57, 95% CI [−0.68, −0.46], P < 0.001). Beraprost sodium intake had no significant effect on fasting blood sugar (FBS), hemoglobin A1c (HbA1c), cholesterol (TC), triglycerides (TG), HDL-C, LDL-C, systolic blood pressure (SBP), diastolic blood pressure (DBP), and creatinine (Cr) in patients with diabetes receiving beraprost sodium in comparison with the controls.

Conclusion

Our meta-analysis revealed that beraprost sodium administration significantly decreased BUN and cystatin C levels in patients with diabetes. However, no significant effect was observed on the cardiometabolic profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Alrawahi AH, Rizvi SG, Al-Riyami D, Al-Anqoodi Z (2012) Prevalence and risk factors of diabetic nephropathy in omani type 2 diabetics in Al-dakhiliyah region. Oman Med J 27(3):212–216

    Article  Google Scholar 

  2. Kim M, Kim JU, Kim SM, Kim H (2017) Effectiveness of beraprost sodium in maintaining vascular access patency in patients on hemodialysis. Int Urol Nephrol 49(7):1287–1295

    Article  CAS  Google Scholar 

  3. Magee C, Grieve DJ, Watson CJ, Brazil DP (2017) diabetic nephropathy: a tangled web to unweave. Cardiovasc Drugs Ther 31(5–6):579–592

    Article  Google Scholar 

  4. Lièvre M, Morand S, Besse B, Fiessinger JN, Boissel JP (2000) Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 102(4):426–431

    Article  Google Scholar 

  5. Guan J, Long L, Chen YQ, Yin Y, Li L, Zhang CX et al (2014) Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy. GMR 13(2):4154–4158

    Article  CAS  Google Scholar 

  6. Li S, Wang Y, Chen L, Wang Z, Liu G, Zuo B et al (2019) Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels. J Mol Med (Berl) 97(6):777–791

    Article  CAS  Google Scholar 

  7. Choi YM, Kwon HS, Choi KM, Lee WY, Hong EG (2019) Short-term effects of beraprost sodium on the markers for cardiovascular risk prediction in type 2 diabetic patients with microalbuminuria. Endocrinol Metab 34(4):398–405

    Article  CAS  Google Scholar 

  8. Xu X, Pan X, Li S (2020) Prospective analysis of the efficacy of beraprost sodium combined with alprostadil on diabetic nephropathy and influence on rennin-angiotensin system and TNF-α. Exp Ther Med 19(1):639–645

    CAS  PubMed  Google Scholar 

  9. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097

    Article  Google Scholar 

  10. Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions, version 5.1. 0

  11. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558

    Article  Google Scholar 

  12. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

    Article  CAS  Google Scholar 

  13. Owada A, Suda S, Hata T (2002) Effect of long-term administration of prostaglandin I(2) in incipient diabetic nephropathy. Nephron 92(4):788–796

    Article  CAS  Google Scholar 

  14. Goya K, Otsuki M, Xu X, Kasayama S (2003) Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism 52(2):192–198

    Article  CAS  Google Scholar 

  15. Shin S, Kim KJ, Chang HJ, Lee BW, Yang WI, Cha BS et al (2012) The effect of oral prostaglandin analogue on painful diabetic neuropathy: a double-blind, randomized, controlled trial. Diabetes Obes Metab 15(2):185–188

    Article  Google Scholar 

  16. Shima A, Miyamoto M, Kubota Y, Takagi G, Shimizu W (2015) Beraprost sodium protects against diabetic nephropathy in patients with arteriosclerosis obliterans: a prospective, randomized, open-label study. J Nippon Med Sch 82(2):84–91

    Article  CAS  Google Scholar 

  17. Xia J, Shen S (2019) Efficacy of beraprost sodium in the treatment of diabetic nephropathy in elderly patients. Int J Clin Exp Med 12(5):5927–5932

    CAS  Google Scholar 

  18. Barbieri SS, Amadio P, Gianellini S, Tarantino E, Zacchi E, Veglia F et al (2012) Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner. Circulation 126(11):1373–1384

    Article  CAS  Google Scholar 

  19. Vizza CD, Sciomer S, Morelli S, Lavalle C, Di Marzio P, Padovani D et al (2001) Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 86(6):661–665

    Article  CAS  Google Scholar 

  20. Alonso-Coello P, Bellmunt S, McGorrian C, Anand SS, Guzman R, Criqui MH et al (2012) Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e669S – e690

    Article  CAS  Google Scholar 

  21. Palatini P (2012) Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 27(5):1708–1714

    Article  Google Scholar 

Download references

Acknowledgements

The authors wish to thank the authors of the primary studies.

Funding

The authors declare no specific funding for this work.

Author information

Authors and Affiliations

  1. Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

    Peyman Nowrouzi-Sohrabi

  2. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

    Peyman Nowrouzi-Sohrabi, Kamran Hessami & Shahla Rezaei

  3. Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran

    Reza Tabrizi

  4. Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran

    Reza Tabrizi

  5. Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Kamran Hessami

  6. Faculty of Pharmacy, Department of Clinical Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

    Mojtaba Shabani-Borujeni

  7. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Mahnaz Hosseini-Bensenjan

  8. Nutrition Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Shahla Rezaei & Mohammad Jalali

  9. Department of Radiology, Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Pedram Keshavarz

  10. Department of Epidemiology, Erasmus MC-University Medical Center, Rotterdam, Netherlands

    Fariba Ahmadizar

Authors
  1. Peyman Nowrouzi-Sohrabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reza Tabrizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kamran Hessami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mojtaba Shabani-Borujeni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mahnaz Hosseini-Bensenjan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shahla Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mohammad Jalali
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pedram Keshavarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fariba Ahmadizar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Reza Tabrizi.

Ethics declarations

Conflict of interest

The authors declare there are no competing interests.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 77 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nowrouzi-Sohrabi, P., Tabrizi, R., Hessami, K. et al. The effects of beraprost sodium on renal function and cardiometabolic profile in patients with diabetes mellitus: a systematic review and meta-analysis of clinical trials. Int Urol Nephrol 54, 111–120 (2022). https://doi.org/10.1007/s11255-021-02887-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-021-02887-7

Keywords

Search

Navigation